CN113667062A - 一种抗癌活性姜黄素包裹LTBX-g-HEMA纳米粒的合成方法 - Google Patents
一种抗癌活性姜黄素包裹LTBX-g-HEMA纳米粒的合成方法 Download PDFInfo
- Publication number
- CN113667062A CN113667062A CN202110999303.9A CN202110999303A CN113667062A CN 113667062 A CN113667062 A CN 113667062A CN 202110999303 A CN202110999303 A CN 202110999303A CN 113667062 A CN113667062 A CN 113667062A
- Authority
- CN
- China
- Prior art keywords
- hema
- bagasse xylan
- theanine
- stirring
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229940109262 curcumin Drugs 0.000 title claims abstract description 45
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 title claims abstract description 36
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 32
- 239000004148 curcumin Substances 0.000 title claims abstract description 25
- 235000012754 curcumin Nutrition 0.000 title claims abstract description 18
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 title claims abstract description 18
- 230000001093 anti-cancer Effects 0.000 title claims abstract description 9
- 238000001308 synthesis method Methods 0.000 title claims abstract description 6
- 241000609240 Ambelania acida Species 0.000 claims abstract description 85
- 239000010905 bagasse Substances 0.000 claims abstract description 85
- 229920001221 xylan Polymers 0.000 claims abstract description 68
- 150000004823 xylans Chemical class 0.000 claims abstract description 68
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims abstract description 33
- 239000000463 material Substances 0.000 claims abstract description 18
- 229940026510 theanine Drugs 0.000 claims abstract description 16
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 claims abstract description 12
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000003999 initiator Substances 0.000 claims abstract description 12
- 239000000178 monomer Substances 0.000 claims abstract description 11
- 235000019832 sodium triphosphate Nutrition 0.000 claims abstract description 11
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims abstract description 10
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- PBIDWHVVZCGMAR-UHFFFAOYSA-N 1-methyl-3-prop-2-enyl-2h-imidazole Chemical class CN1CN(CC=C)C=C1 PBIDWHVVZCGMAR-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229910001870 ammonium persulfate Inorganic materials 0.000 claims abstract description 5
- 238000003756 stirring Methods 0.000 claims description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- 239000000243 solution Substances 0.000 claims description 27
- 238000001035 drying Methods 0.000 claims description 24
- 239000012153 distilled water Substances 0.000 claims description 21
- 238000005303 weighing Methods 0.000 claims description 15
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 239000000839 emulsion Substances 0.000 claims description 12
- 239000012065 filter cake Substances 0.000 claims description 12
- 229920000578 graft copolymer Polymers 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 239000002244 precipitate Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 239000011521 glass Substances 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 6
- 229920000053 polysorbate 80 Polymers 0.000 claims description 6
- 230000001376 precipitating effect Effects 0.000 claims description 6
- 238000000967 suction filtration Methods 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 3
- 239000000440 bentonite Substances 0.000 claims description 3
- 229910000278 bentonite Inorganic materials 0.000 claims description 3
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 235000010445 lecithin Nutrition 0.000 claims description 3
- 229940067606 lecithin Drugs 0.000 claims description 3
- 239000000787 lecithin Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 2
- AYEKOFBPNLCAJY-UHFFFAOYSA-O thiamine pyrophosphate Chemical compound CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N AYEKOFBPNLCAJY-UHFFFAOYSA-O 0.000 claims 3
- UNXRWKVEANCORM-UHFFFAOYSA-I triphosphate(5-) Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O UNXRWKVEANCORM-UHFFFAOYSA-I 0.000 abstract description 8
- 206010028980 Neoplasm Diseases 0.000 abstract description 7
- 238000000034 method Methods 0.000 abstract description 5
- 239000002028 Biomass Substances 0.000 abstract description 3
- 238000003889 chemical engineering Methods 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 239000012847 fine chemical Substances 0.000 abstract description 3
- 230000002194 synthesizing effect Effects 0.000 abstract description 3
- 239000003054 catalyst Substances 0.000 abstract description 2
- 229920001577 copolymer Polymers 0.000 abstract description 2
- 238000004132 cross linking Methods 0.000 abstract description 2
- 238000004945 emulsification Methods 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 230000035755 proliferation Effects 0.000 abstract description 2
- 238000007348 radical reaction Methods 0.000 abstract description 2
- 150000003254 radicals Chemical class 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 229910052708 sodium Inorganic materials 0.000 abstract description 2
- 239000011734 sodium Substances 0.000 abstract description 2
- 239000002904 solvent Substances 0.000 abstract description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 239000000047 product Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 239000012086 standard solution Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000005886 esterification reaction Methods 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000032050 esterification Effects 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 229940041181 antineoplastic drug Drugs 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 3
- 238000002329 infrared spectrum Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 239000008709 Curare Substances 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 238000002479 acid--base titration Methods 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000003032 molecular docking Methods 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000004626 scanning electron microscopy Methods 0.000 description 2
- GXFZCDMWGMFGFL-KKXMJGKMSA-N (+)-Tubocurarine chloride hydrochloride Chemical compound [Cl-].[Cl-].C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CC[NH+]3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 GXFZCDMWGMFGFL-KKXMJGKMSA-N 0.000 description 1
- RHCSKNNOAZULRK-APZFVMQVSA-N 2,2-dideuterio-2-(3,4,5-trimethoxyphenyl)ethanamine Chemical compound NCC([2H])([2H])C1=CC(OC)=C(OC)C(OC)=C1 RHCSKNNOAZULRK-APZFVMQVSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241001279009 Strychnos toxifera Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- -1 acrylic ester Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000235 effect on cancer Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F251/00—Macromolecular compounds obtained by polymerising monomers on to polysaccharides or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nanotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- General Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Physics & Mathematics (AREA)
- Manufacturing & Machinery (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种抗癌活性姜黄素包裹LTBX‑g‑HEMA纳米粒的合成方法。以蔗渣木聚糖为原料，甲基丙烯酸羟乙酯为接枝单体，过硫酸铵为引发剂，通过自由基反应合成蔗渣木聚糖‑g‑HEMA共聚物；然后在氯化1‑烯丙基‑3‑甲基咪唑溶剂中，以4‑二甲氨基吡啶为催化剂合成茶氨酸酯化蔗渣木聚糖‑g‑HEMA；采用乳化分散‑三聚磷酸钠交联法制备姜黄素包裹蔗渣木聚糖茶氨酸酯‑g‑HEMA纳米粒即LTBX‑g‑HEMA‑Cur纳米粒。本发明在蔗渣木聚糖基础上引入活性基团，合成具有抑制肿瘤增殖功能的蔗渣木聚糖茶氨酸酯‑g‑HEMA‑Cur纳米粒，扩大了其在医药、生物质材料与精细化工等领域的应用范围。
Description
技术领域
本发明涉及精细化工领域，特别是一种具有抗癌活性的蔗渣木聚糖茶氨酸酯-g-HEMA-姜黄素纳米粒即LTBX-g-HEMA-Cur纳米粒的合成方法。
背景技术
姜黄素(Cur)能够调节基因活性和表达，破坏大肠癌细胞，具有促进健康细胞恢复的功能，能够降低抗癌药物对人体的毒害作用。它还可以促进抗血管生成，意味着可以帮助阻断癌细胞生长所必须的额外的血液供应。但因其不溶于水在投递药物时，无法让血液承载，人体所能够吸收的量极少。而蔗渣木聚糖作为良好的生物质抗癌材料对多种癌细胞均能起到一定的抑制效果，但其活性和利用率较低，而目前诸多研究主要是对其进行单方面改性，由此产生的功效也具有一定的局限性。如果将具有天然抗癌活性的蔗渣木聚糖通过复合改性引入活性基团，达到优化其物理化学性质的目的，且将采用物理技术制备姜黄素包裹的蔗渣木聚糖衍生物纳米级颗粒，可运送至人体癌细胞处，通过协同增效抑制癌细胞的增长和扩散。
茶氨酸(LT)与抗肿瘤药并用时，能提高多种抗肿瘤药的活性。茶氨酸能阻止抗肿瘤药从肿瘤细胞中流出，增强了抗癌效果。茶氨酸还能调节脂质过氧化水平、减轻抗肿瘤药引起的白血球及骨髓细胞的减少等副作用。故用茶氨酸作为酯化剂，通过酯化反应将活性基团引入到蔗渣木聚糖衍生物主链上。而通过接枝的方式引入甲基丙烯酸羟乙酯(HEMA)等活性基团，可扩大成为抗肿瘤靶点的几率。同时，蔗渣木聚糖衍生物与姜黄素纳米颗粒进行交联，得到的产物蔗渣木聚糖茶氨酸酯-g-HEMA-Cur纳米颗粒，包埋效率大幅度提高，不仅在水溶液中具有较好的缓释性能，并且其热稳定性和抗肿瘤活性都得到显著提高。由分子对接可知，该纳米粒与6USZ发生氢键作用的氨基酸残基为ASP-69、GLU-63、GLN-61，氢键键长分别为2.0、2.0、
氢键是维系受体蛋白与配体分子结合稳定性的重要作用力，这些氢键网络增强了配体与受体蛋白的结合力,从而表现出对癌细胞的高效抑制作用。
本发明以蔗渣木聚糖为主要原料，甲基丙烯酸羟乙酯为接枝单体，过硫酸铵为引发剂，通过自由基反应合成蔗渣木聚糖-g-HEMA共聚物；然后在氯化1-烯丙基-3-甲基咪唑溶剂中，以4-二甲氨基吡啶为催化剂合成茶氨酸酯化蔗渣木聚糖-g-HEMA即LTBX-g-HEMA；最后采用乳化分散-三聚磷酸钠交联法制备姜黄素包裹蔗渣木聚糖茶氨酸酯-g-HEMA纳米粒即LTBX-g-HEMA-Cur纳米粒。
发明内容
本发明旨在通过复合改性引入多种生物活性基团，增加蔗渣木聚糖分子中活性基团的种类和数量，为研究新型多靶点药物载体奠定基础，提供一种抗癌活性姜黄素包裹蔗渣木聚糖荼氨酸酯-g-HEMA纳米粒的合成方法。
本发明的具体步骤为：
(1)分别将5.0～7.0g蔗渣木聚糖置于60℃真空恒温干燥箱中干燥24小时，分别得干基蔗渣木聚糖。
(2)称取0.8～1.5g过硫酸铵于50mL烧杯中，加入10～20mL蒸馏水配成引发剂溶液，室温下充分搅拌均匀后，倒入100mL恒压滴液漏斗中，备用。
(3)量取4.0～5.0mL分析纯甲基丙烯酸羟乙酯(HEMA)置于50mL烧杯中，加入20～25mL蒸馏水、0.1～0.2mL化学纯吐温-80，室温下搅拌溶解均匀后得单体乳化液，倒入另一100mL恒压滴液漏斗中，备用。
(4)称取4.0～6.0g步骤(1)所得干基蔗渣木聚糖置于250mL四口烧瓶中，再加入50～100mL蒸馏水，升温至50～60℃，搅拌30～50分钟，得蔗渣木聚糖活化液。
(5)先滴加三分之一步骤(2)所得引发剂溶液至步骤(4)所得蔗渣木聚糖活化液中，滴加时间控制在40～60分钟，滴加完毕后继续搅拌20～30分钟。然后开始同时滴加步骤(3)所得单体溶液和剩余三分之二步骤(2)所得引发剂溶液，控制体系温度在50～70℃、滴加时间为2～5小时，滴加完毕后继续反应1～3小时，将物料冷却至室温。
(6)将步骤(5)所得物料用50～70mL分析纯环己烷沉析20～30分钟，析出沉淀后抽滤。依次分别量取10～15mL分析纯无水乙醇和10～20mL分析纯环己烷对滤饼进行洗涤、抽滤2～3次。将最后抽滤所得滤饼置于60℃恒温干燥箱中干燥24小时至恒重，得粗蔗渣木聚糖-g-HEMA接枝共聚物。
(7)将步骤(5)所得粗蔗渣木聚糖-g-HEMA接枝共聚物置于索氏抽提器中，加入50～70mL分析纯环己烷抽提24小时；抽提完毕后取出物料放入表面皿中，置于60℃真空恒温干燥箱中干燥24小时至恒重，得纯蔗渣木聚糖-g-HEMA接枝共聚物。
(8)将40.0～60.0g氯化1-烯丙基-3-甲基咪唑加入到250mL四口烧瓶中，加入15～25mL蒸馏水，将四口烧瓶置于水浴锅中加热至50～60℃，使氯化1-烯丙基-3-甲基咪唑溶解为透明的黄色液体；然后将2.0～4.0g干燥的蔗渣木聚糖-g-HEMA、0.2～1.0g 4-二甲氨基吡啶、0.2～0.35g膨润土加入四口烧瓶中，搅拌分散0.5～1小时；称取2.0～4.0g茶氨酸，均匀分三次每次间隔20分钟加入四口烧瓶中，控制反应温度在60～70℃，搅拌反应4～6小时。反应结束后将体系温度降至室温。
(9)将步骤(8)所得物料用50～70mL分析纯无水乙醇沉析20～30分钟，然后抽滤；每次分别量取10～15mL分析纯无水乙醇和10～25mL分析纯环己烷对滤饼进行洗涤、抽滤2～3次。将所得滤饼置于60℃恒温干燥箱中干燥24小时至恒重，得蔗渣木聚糖-g-HEMA衍生物。
(10)将0.5～1.0g姜黄素加入100mL四口烧瓶中，再加入20～30mL分析纯无水乙醇，置于30℃恒温水浴中搅拌20～30分钟；然后依次加入0.2～0.3g食用卵磷脂和1.0～1.5mL化学纯吐温-80，搅拌0.5～1.0小时，配制成姜黄素乳化液。
(11)称取3.5～4.0g三聚磷酸钠(TPP)加入250mL烧杯中，再加入130～160mL蒸馏水，室温下搅拌均匀得TPP溶液，备用。
(12)称取5～7.5g蔗渣木聚糖茶氨酸酯-g-HEMA于500mL四口烧瓶中，加入200～220mL蒸馏水，室温下搅拌均匀后，将其置于高速搅拌机中，以800r/min的速率搅拌分散1～3小时，得蔗渣木聚糖茶氨酸酯-g-HEMA混合液。
(13)将步骤(10)所得姜黄素乳化液和步骤(11)所得TPP溶液同步滴入步骤(12)所得蔗渣木聚糖茶氨酸酯-g-HEMA混合液中，滴加时间控制在30～60分钟；滴加完毕后，继续搅拌0.5～1.0小时；设置4000r/min离心速率，离心0.5～1.0小时后分离上清液，收集沉淀；每次分别用15～25mL蒸馏水洗涤、离心5～10分钟，分离上清液，收集沉淀，重复操作2～3次；最后将所得沉淀物料送入-20～-18℃冷冻干燥机中冷冻干燥24小时，得蔗渣木聚糖茶氨酸酯-g-HEMA-Cur纳米粒即LTBX-g-HEMA-Cur纳米粒。
(14)利用酸碱滴定法对产物蔗渣木聚糖茶氨酸酯-g-HEMA的酯化取代度进行测定，具体步骤如下：精确称取约0.5g LTBX-g-HEMA样品放入50mL锥形瓶中，向锥形瓶中加入20mL去离子水并充分摇匀，加入2～3滴酚酞指示剂，用浓度为0.5mol/L的NaOH标准溶液将样品溶液滴定至浅红色，且能维持30秒内红色不褪去。加入2.5mL浓度0.5mol/L的氢氧化钠溶液，摇匀，密封，在室温下置于电动振荡器震荡皂化4小时后，用浓度为0.5mol/L的盐酸标准溶液滴定至溶液体系为无色，记录滴定消耗的盐酸标准溶液体积为V1；在相同条件下，用蔗渣木聚糖接枝共聚物进行空白滴定，记录消耗的盐酸标准溶液体积V0。目标产物中羧酸酰基的质量分数(wc)、蔗渣木聚糖茶氨酸酯-g-HEMA的酯化取代度(DS)的计算公式如下：
式中：
wc——目标产物中含有羧酸酰基的质量分数，％；
V0——进行空白滴定消耗盐酸标准溶液体积，单位mL；
V1——滴定目标产物消耗的盐酸标准溶液体积，单位mL；
CHCl——盐酸标准溶液浓度，单位moL/L；
m——目标产物样品的质量，单位g；
DS——LTBX-g-HEMA的酯化取代度；
M——羧酸酰基的摩尔质量，g/mol；
132——木聚糖脱水单元的相对分子质量。
本发明在蔗渣木聚糖基础上引入活性基团，合成具有抑制肿瘤增殖功能的蔗渣木聚糖茶氨酸酯-g-HEMA-Cur纳米粒，扩大了其在医药、生物质材料与精细化工等领域的应用范围。
附图说明
图1为原蔗渣木聚糖的IR图。
图2为本发明实施例制备的蔗渣木聚糖茶氨酸酯-g-HEMA和蔗渣木聚糖茶氨酸酯-g-HEMA-姜黄素纳米粒的IR图。
图3为原蔗渣木聚糖、蔗渣木聚糖-g-HEMA和蔗渣木聚糖茶氨酸酯-g-HEMA的XRD图。
图4为本发明实施例制备的蔗渣木聚糖茶氨酸酯-g-HEMA-姜黄素纳米粒的XRD图。
图5为原蔗渣木聚糖的SEM照片。
图6为本发明实施例制备的蔗渣木聚糖茶氨酸酯-g-HEMA的SEM照片。
图7为本发明实施例制备的蔗渣木聚糖茶氨酸酯-g-HEMA-姜黄素纳米粒的SEM照片。
图8为蔗渣木聚糖茶氨酸酯-g-HEMA-姜黄素纳米粒与6USZ受体蛋白对接图
图9为蔗渣木聚糖茶氨酸酯-g-HEMA-姜黄素纳米粒与6USZ受体蛋白空腔对接图
具体实施方式
实施例：
(1)分别将6.0g蔗渣木聚糖置于60℃真空恒温干燥箱中干燥24小时，分别得干基蔗渣木聚糖。
(2)称取1.1g过硫酸铵于50mL烧杯中，加入15mL蒸馏水配成引发剂溶液，室温下充分搅拌均匀后，倒入100mL恒压滴液漏斗中，备用。
(3)量取4.6mL分析纯甲基丙烯酸羟乙酯(HEMA)置于50mL烧杯中，加入20mL蒸馏水、0.15mL化学纯吐温-80，室温下搅拌溶解均匀后得单体乳化液，倒入另一100mL恒压滴液漏斗中，备用。
(4)称取5.0g步骤(1)所得干基蔗渣木聚糖置于250mL四口烧瓶中，再加入75mL蒸馏水，升温至50℃，搅拌30分钟，得蔗渣木聚糖活化液。
(5)先滴加三分之一步骤(2)所得引发剂溶液至步骤(4)所得蔗渣木聚糖活化液中，滴加时间控制在50分钟，滴加完毕后继续搅拌30分钟。然后开始同时滴加步骤(3)所得单体溶液和剩余三分之二步骤(2)所得引发剂溶液，控制体系温度在60℃、滴加时间为3小时，滴加完毕后继续反应2小时，将物料冷却至室温。
(6)将步骤(5)所得物料用60mL分析纯环己烷沉析30分钟，析出沉淀后抽滤。依次分别量取10mL分析纯无水乙醇和15mL分析纯环己烷对滤饼进行洗涤、抽滤3次。将最后抽滤所得滤饼置于60℃恒温干燥箱中干燥24小时至恒重，得粗蔗渣木聚糖-g-HEMA接枝共聚物。
(7)将步骤(5)所得粗蔗渣木聚糖-g-HEMA接枝共聚物置于索氏抽提器中，加入60mL分析纯环己烷抽提24小时；抽提完毕后取出物料放入表面皿中，置于60℃真空恒温干燥箱中干燥24小时至恒重，得纯蔗渣木聚糖-g-HEMA接枝共聚物。
(8)将60.0g氯化1-烯丙基-3-甲基咪唑加入到250mL四口烧瓶中，加入25mL蒸馏水，将四口烧瓶置于水浴锅中加热至60℃，使氯化1-烯丙基-3-甲基咪唑溶解为透明的黄色液体；然后将4.0g干燥的蔗渣木聚糖-g-HEMA、0.4g 4-二甲氨基吡啶、0.25g膨润土加入四口烧瓶中，搅拌分散0.5小时；称取4.0g茶氨酸，均匀分三次每次间隔20分钟加入四口烧瓶中，控制反应温度在60℃，搅拌反应5小时。反应结束后将体系温度降至室温。
(9)将步骤(8)所得物料用50mL分析纯无水乙醇沉析30分钟，然后抽滤；每次分别量取15mL分析纯无水乙醇和25mL分析纯环己烷对滤饼进行洗涤、抽滤3次。将所得滤饼置于60℃恒温干燥箱中干燥24小时至恒重，得蔗渣木聚糖-g-HEMA衍生物。
(10)将0.8g姜黄素加入100mL四口烧瓶中，再加入30mL分析纯无水乙醇，置于30℃恒温水浴中搅拌30分钟；然后依次加入0.25g食用卵磷脂和1.25mL化学纯吐温-80，搅拌0.5小时，配制成姜黄素乳化液。
(11)称取3.75g三聚磷酸钠(TPP)加入250mL烧杯中，再加入150mL蒸馏水，室温下搅拌均匀得TPP溶液，备用。
(12)称取6.5g蔗渣木聚糖茶氨酸酯-g-HEMA于500mL四口烧瓶中，加入210mL蒸馏水，室温下搅拌均匀后，将其置于高速搅拌机中，以800r/min的速率搅拌分散2小时，得蔗渣木聚糖茶氨酸酯-g-HEMA混合液。
(13)将步骤(10)所得姜黄素乳化液和步骤(11)所得TPP溶液同步滴入步骤(12)所得蔗渣木聚糖茶氨酸酯-g-HEMA混合液中，滴加时间控制在60分钟；滴加完毕后，继续搅拌1.0小时；设置4000r/min离心速率，离心1.0小时后分离上清液，收集沉淀；每次分别用25mL蒸馏水洗涤、离心10分钟，分离上清液，收集沉淀，重复操作3次；最后将所得沉淀物料送入-25℃冷冻干燥机中冷冻干燥24小时，得蔗渣木聚糖茶氨酸酯-g-HEMA-Cur纳米粒即LTBX-g-HEMA-Cur纳米粒。
(14)利用酸碱滴定法对LTBX-g-HEMA的酯化取代度进行测定，测得DS为0.75。
(15)经SEM分析可知，LTBX-g-HEMA-Cur的形貌呈颗粒状，平均粒径在100nm左右。
对BX，BX-g-HEMA，LTBX-g-HEMA，LTBX-g-HEMA-Cur进行IR分析可知，BX的IR谱图在890～875cm-1处为β-D糖苷键构型的木聚糖分子骨架振动峰，3432cm-1处为木聚糖侧链-OH的伸缩振动吸收峰；BX-g-HEMA的IR谱图在3430cm-1和1738cm-1处分别出现了-OH伸缩振动吸收峰及酯羰基—C＝O的伸缩振动特征吸收峰，同时在1080cm-1和1171cm-1处出现明显的丙烯酸酯C—O的伸缩振动吸收峰；LTBX-g-HEMA的IR谱图在3338cm-1出现—NH的伸缩振动峰，2983cm-1和2940cm-1处的峰为—CH3的伸缩振动峰，1655cm-1处为C＝O伸缩振动峰；LTBX-g-HEMA-Cur的IR谱图在3514cm-1处-OH的特征峰消失，在1655cm-1处C＝O的特征峰消失，表明LTBX-g-HEMA与Cur之间发生了相互作用。XRD分析可知，在衍射角10°、11°、13°、19°、25°和33°处，BX的X射线粉末衍射图出现了较强的衍射峰，晶型较弱，说明BX为无定形结构；BX-g-HEMA在19°、22°、23°、24°、26°和35°等处为新的衍射峰，19°～24°范围内BX-g-HEMA的X射线粉末图峰形宽而钝，晶型较弱的BX-g-HEMA为无定形结构；LTBX-g-HEMA在10°、28°和30°等处出现新的衍射峰，18°～25°范围内峰面积细窄且高，证明LTBX-g-HEMA的结晶度增大，晶体区域扩大；LTBX-g-HEMA-Cur的X射线粉末图峰形宽而钝，在衍射角为25°和31°处出现新的衍射峰，在15°～20°范围内峰形宽且低，证明LTBX-g-HEMA-Cur的结晶低，晶体区域减小。经SEM分析可知，BX的形貌类似球状颗粒，表面相对光滑，球形大多相对完整；BX-g-HEMA的形貌发生了较大的变化，形貌长而扁，表面有较多排列分布的云状颗粒；LTBX-g-HEMA经茶氨酸酯化后形貌呈棒状结构，棒的直径大约500～700nm；LTBX-g-HEMA与Cur复合后，形貌呈颗粒状，平均粒径在100nm左右，但是粒子有一定程度黏连，可能是由于氢键作用的结果。经分子对接可知，LTBX-g-HEMA-Cur纳米粒与受体蛋白4Z55、5JT2、6NJA、6USZ相互作用，其最佳结合自由能分别为-21.26、-25.15、-23.79、-25.41kJ/mol；与6USZ发生氢键作用的氨基酸残基为ASP-69、GLU-63、GLN-61，氢键键长分别为2.0、2.0、
结果显示其对多种癌细胞具有高效抑制作用。
Claims (1)
1.一种具有抗癌活性的蔗渣木聚糖茶氨酸酯-g-HEMA-姜黄素纳米粒即LTBX- g-HEMA-Cur纳米粒的合成方法，其特征在于具体步骤为：
(1)分别将5.0~7.0g蔗渣木聚糖置于60℃真空恒温干燥箱中干燥24小时，分别得干基蔗渣木聚糖；
(2)称取0.8~1.5g过硫酸铵于50mL烧杯中，加入10~20mL蒸馏水配成引发剂溶液，室温下充分搅拌均匀后，倒入100mL恒压滴液漏斗中，备用；
(3)量取4.0~5.0mL分析纯甲基丙烯酸羟乙酯置于50mL烧杯中，加入20~25mL蒸馏水、0.1~0.2mL化学纯吐温-80，室温下搅拌溶解均匀后得单体乳化液，倒入另一100mL恒压滴液漏斗中，备用；
(4)称取4.0~6.0g步骤(1)所得干基蔗渣木聚糖置于250mL四口烧瓶中，再加入50~100mL蒸馏水，升温至50~60℃，搅拌30~50分钟，得蔗渣木聚糖活化液；
(5)先滴加三分之一步骤(2)所得引发剂溶液至步骤(4)所得蔗渣木聚糖活化液中，滴加时间控制在40~60分钟，滴加完毕后继续搅拌20~30分钟；然后开始同时滴加步骤(3)所得单体溶液和剩余三分之二步骤(2)所得引发剂溶液，控制体系温度在50~70℃、滴加时间为2~5小时，滴加完毕后继续反应1~3小时，将物料冷却至室温；
(6)将步骤(5)所得物料用50~70mL分析纯环己烷沉析20~30分钟，析出沉淀后抽滤；依次分别量取10~15mL分析纯无水乙醇和10~20mL分析纯环己烷对滤饼进行洗涤、抽滤2~3次；将最后抽滤所得滤饼置于60℃恒温干燥箱中干燥24小时至恒重，得粗蔗渣木聚糖-g-HEMA接枝共聚物；
(7)将步骤(5)所得粗蔗渣木聚糖-g-HEMA接枝共聚物置于索氏抽提器中，加入50~70mL分析纯环己烷抽提24小时；抽提完毕后取出物料放入表面皿中，置于60℃真空恒温干燥箱中干燥24小时至恒重，得纯蔗渣木聚糖-g-HEMA接枝共聚物；
(8)将40.0~60.0g氯化1-烯丙基-3-甲基咪唑加入到250mL四口烧瓶中，加入15~25mL蒸馏水，将四口烧瓶置于水浴锅中加热至50~60℃，使氯化1-烯丙基-3-甲基咪唑溶解为透明的黄色液体；然后将2.0~4.0g 干燥的蔗渣木聚糖-g-HEMA、0.2~1.0g 4-二甲氨基吡啶、0.2~0.35g膨润土加入四口烧瓶中，搅拌分散0.5~1小时；称取2.0~4.0g茶氨酸，均匀分三次每次间隔20分钟加入四口烧瓶中，控制反应温度在60~70℃，搅拌反应4~6小时；反应结束后将体系温度降至室温；
(9)将步骤(8)所得物料用50~70mL分析纯无水乙醇沉析20~30分钟，然后抽滤；每次分别量取10~15mL分析纯无水乙醇和10~25mL分析纯环己烷对滤饼进行洗涤、抽滤2~3次；将所得滤饼置于60℃恒温干燥箱中干燥24小时至恒重，得蔗渣木聚糖-g-HEMA衍生物；
(10)将0.5~1.0g姜黄素加入100mL四口烧瓶中，再加入20~30 mL分析纯无水乙醇，置于30℃恒温水浴中搅拌20~30分钟；然后依次加入0.2~0.3 g食用卵磷脂和1.0~1.5mL化学纯吐温-80，搅拌0.5~1.0小时，配制成姜黄素乳化液；
(11)称取3.5~4.0g三聚磷酸钠即TPP加入250mL烧杯中，再加入130~160mL蒸馏水，室温下搅拌均匀得TPP溶液，备用；
(12)称取5~7.5g蔗渣木聚糖茶氨酸酯-g-HEMA于500mL四口烧瓶中，加入200~220mL蒸馏水，室温下搅拌均匀后，将其置于高速搅拌机中，以800r/min的速率搅拌分散1~3小时，得蔗渣木聚糖茶氨酸酯-g-HEMA混合液；
(13)将步骤(10)所得姜黄素乳化液和步骤(11)所得TPP溶液同步滴入步骤(12)所得蔗渣木聚糖茶氨酸酯-g-HEMA混合液中，滴加时间控制在30~60分钟；滴加完毕后，继续搅拌0.5~1.0小时;设置 4000 r/min 离心速率，离心0.5~1.0小时后分离上清液，收集沉淀；每次分别用15~25mL蒸馏水洗涤、离心5~10分钟，分离上清液，收集沉淀，重复操作2~3次；最后将所得沉淀物料送入-20~-18℃冷冻干燥机中冷冻干燥24小时，得蔗渣木聚糖茶氨酸酯-g-HEMA-Cur纳米粒即LTBX-g- HEMA-Cur纳米粒。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110999303.9A CN113667062A (zh) | 2021-08-28 | 2021-08-28 | 一种抗癌活性姜黄素包裹LTBX-g-HEMA纳米粒的合成方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110999303.9A CN113667062A (zh) | 2021-08-28 | 2021-08-28 | 一种抗癌活性姜黄素包裹LTBX-g-HEMA纳米粒的合成方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113667062A true CN113667062A (zh) | 2021-11-19 |
Family
ID=78547145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110999303.9A Withdrawn CN113667062A (zh) | 2021-08-28 | 2021-08-28 | 一种抗癌活性姜黄素包裹LTBX-g-HEMA纳米粒的合成方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113667062A (zh) |
-
2021
- 2021-08-28 CN CN202110999303.9A patent/CN113667062A/zh not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107540789B (zh) | 生物活性衍生物蔗渣木聚糖丁香酸酯-g-AM的合成方法 | |
| CN107417857B (zh) | 抗癌活性衍生物蔗渣木聚糖丁香酸酯-g-AM/MMA的合成方法 | |
| CN102145173B (zh) | 人血清白蛋白复合的疏水改性普鲁兰多糖纳米粒子及制备方法 | |
| JP5709219B2 (ja) | 金−銀コアシェルナノロッド粒子及びその製造方法 | |
| RU2482849C1 (ru) | Способ получения микрокапсул лекарственных препаратов группы цефалоспоринов в конжаковой камеди в диэтиловом эфире | |
| CN100571781C (zh) | 生物素化普鲁兰多糖纳米微粒及其制备方法 | |
| CN109400812A (zh) | 一种抗肿瘤活性交联蔗渣木聚糖咖啡酸酯-g-AM/BA的合成方法 | |
| CN108641092B (zh) | 基于氢键的超分子聚合物复合胶束的制备方法 | |
| Gang et al. | Synthesis and biological evaluation of fluorescent hyaluronic acid modified amorphous calcium phosphate drug carriers for tumor-targeting | |
| CN1290505C (zh) | 载5－氟尿嘧啶药物的pH敏感可控释放纳米粒及制备方法 | |
| CN113667062A (zh) | 一种抗癌活性姜黄素包裹LTBX-g-HEMA纳米粒的合成方法 | |
| CN113698538A (zh) | 一种负载姜黄素的LTBX-g-HEMA/EGDMA纳米粒的制备方法 | |
| CN113842373B (zh) | 一种姜黄素包裹LTBX-g-EGDMA/HEMA/IMA纳米粒的制备方法 | |
| CN113736023A (zh) | 一种活性姜黄素包裹BX-g-HEMA琥珀酸酯纳米颗粒的制备方法 | |
| CN113736024A (zh) | 一种蔗渣木聚糖琥珀酸酯-g-HEMA/EGDMA-Cur的制备方法 | |
| CN113717318A (zh) | 姜黄素包裹bx四元接枝酯化衍生物纳米粒的制备方法 | |
| CN117643637B (zh) | 一种提高姜黄素生物可及性的控制释放载体及其制备方法 | |
| CN113861345A (zh) | 一种抗癌活性蔗渣木聚糖/柚苷-g-HPMA苹果酸酯的合成方法 | |
| CN106432521A (zh) | 一种磷酸酯化白芨多糖的制备方法 | |
| CN113736025A (zh) | 一种活性BX/Nar苹果酸酯-g-HPMA/DEAM/DMDAAC的合成方法 | |
| CN118165185A (zh) | 一种累脱土催化合成复合BX/Res生物质纳米活性材料的方法 | |
| CN113753933B (zh) | 一种Fucoidan/碳酸钙杂化纳米棒及其制备方法 | |
| CN113817103A (zh) | 一种抗癌活性BX/Nar-g-HPMA/DEAM乙酰水杨酸酯的合成方法 | |
| CN110156911A (zh) | 疏水化多糖及其制备方法和应用 | |
| CN113861344A (zh) | 一种蔗渣木聚糖/柚苷-g-HPMA乙酰水杨酸酯的合成方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20211119 |